RESUMO
The mechanisms involved in platelet aggregation induced by epinephrine are unclear. Although epinephrine does not aggregate washed rabbit platelets, platelets made refractory to ADP will aggregate in response to epinephrine in the presence of ADP. We have examined whether the mechanism(s) by which epinephrine induces aggregation of refractory platelets involves fibrinogen binding and Ca2+ association. With normal platelets, ADP causes aggregation, fibrinogen binding and Ca2+ association in a medium containing 0.2 mM 45Ca2+. After 3 min of incubation with ADP, fibrinogen dissociates from platelets, but 45Ca2+ does not. Epinephrine alone does not cause aggregation, fibrinogen binding or 45Ca2+ association. Platelets that are refractory to ADP do not aggregate and bind fibrinogen upon addition of ADP, but aggregate and bind fibrinogen in response to epinephrine, provided ADP is still present. These effects of epinephrine are mediated by the alpha-adrenergic receptor since they are blocked by phentolamine or verapamil and potentiated by propranolol. However, epinephrine-induced aggregation of platelets refractory to ADP does not involve further detectable increase in the amount of 45Ca2+ associated with the platelets.
Assuntos
Difosfato de Adenosina/farmacologia , Epinefrina/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Animais , Plaquetas/metabolismo , Cálcio/sangue , Fibrinogênio/metabolismo , Cinética , Glicoproteínas da Membrana de Plaquetas , Coelhos , Receptores de Superfície Celular/metabolismoRESUMO
Conditions affecting the responses of human platelets to epinephrine were examined. In platelet-rich plasma prepared from blood anticoagulated with hirudin or PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone), epinephrine did not cause shape change or aggregation. In a Tyrode-albumin-apyrase solution containing a concentration of Ca2+ in the physiological range, and fibrinogen, epinephrine in concentrations as high as 40 microM did not induce platelet shape change, caused either no primary aggregation or very slight primary aggregation, and did not induce thromboxane formation, release of dense granule contents, or secondary aggregation. In contrast, in citrated platelet-rich plasma, epinephrine induced two phases of aggregation. This is not attributable to the generation of traces of thrombin since the same effects were evident when blood was taken into a combined citrate-hirudin anticoagulant or a combined citrate-PPACK anticoagulant. In a modified Tyrode-albumin-apyrase solution containing approximately 20 microM Ca2+, 1 mM Mg2+, and fibrinogen, epinephrine induced extensive aggregation after a lag phase, but no primary phase was evident; thromboxane formation and release of dense granule contents accompanied the aggregation response. These responses were also observed when PPACK was included with the acid-citrate-dextrose anticoagulant, and in the washing and resuspending fluids. In the presence of aspirin or the thromboxane receptor blocker BM 13,177 a few small aggregates were detected by particle counting and by scanning electron microscopy; with the latter inhibitor, the platelets in the aggregates retained their disc shape; secondary aggregation and the responses associated with it did not occur.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Plaquetas/efeitos dos fármacos , Epinefrina/farmacologia , Difosfato de Adenosina/farmacologia , Clorometilcetonas de Aminoácidos/farmacologia , Antitrombinas/farmacologia , Plaquetas/ultraestrutura , Cálcio/farmacologia , Sinergismo Farmacológico , Hirudinas/farmacologia , Humanos , Microscopia Eletrônica de Varredura , Agregação Plaquetária/efeitos dos fármacosRESUMO
Ticlopidine was incubated in vitro with rabbit or human washed platelets and aggregations were triggered by submaximal concentrations of adenosine-5'-diphosphate (ADP), arachidonic acid (AA) and Paf-acether (platelet-activating factor), the mediators of the three known pathways of platelet activation. Inhibition of Paf-acether-induced rabbit platelet aggregation was proportional to the concentrations of Ticlopidine used. The same range of inhibition by Ticlopidine was observed when aggregations were triggered by the two other agonists. Human platelet aggregation induced by Paf-acether was also inhibited by Ticlopidine. Inhibition was increased when platelets were rendered insensitive to ADP and AA. Our results show that Ticlopidine inhibits human and rabbit platelet aggregation triggered by Paf-acether through a mechanism not related to the inhibition of the ADP and prostaglandin pathways.
Assuntos
Fator de Ativação de Plaquetas/fisiologia , Agregação Plaquetária/efeitos dos fármacos , Tiofenos/farmacologia , Difosfato de Adenosina/farmacologia , Animais , Ácidos Araquidônicos/farmacologia , Humanos , Fator de Ativação de Plaquetas/antagonistas & inibidores , Coelhos , TiclopidinaRESUMO
Three compounds of the AQ series (benzothienyl-aminoethyl ketone derivatives), i.e. 3178 (benzothienyl-2 N,N-diallyl amino ethyl cetone), 1994 (alpha-benzothienyl-beta-N-morpholino ethyl cetone), and 1989 (benzothienyl-2-beta-N,N-dimethyl amino ethyl cetone) were tested against aggregations triggered by adenosine 5'-diphosphate (ADP), arachidonic acid (AA), paf-acether, thrombin or collagen under different experimental conditions. None of them exhibited a specific inhibitory effect on washed platelets prepared so as to render them specifically sensitive either to ADP, AA or paf-acether. Thus for compound 3178 AQ, the most potent of the three, IC50 values were 2.9 +/- 0.6, 2.9 +/- 1.0 and 4.3 +/- 0.9 uM (means +/- 1 SD of 4 experiments) against ADP, AA or paf-acether respectively. Aggregations triggered by subthreshold concentrations of thrombin were also inhibited by compound 3178 AQ (50 uM) even after washing, showing the persistence of the inhibitory effect. Inhibition was surmountable since addition of a 10 fold greater concentration of thrombin than the subthreshold one induced a full aggregation. When tested on platelet-rich plasma (PRP) higher concentrations of the inhibitors than those used on washed platelets were needed in order to counteract ADP, AA or paf-acether effects. Collagen-induced aggregation was also inhibited by the AQ compounds when tested either in PRP or in whole blood although, in the latter case, high concentrations of the antagonists had to be used. These data show that compounds of the AQ series bear a wide spectrum of activity which makes them potential anti-thrombotic agents.
Assuntos
Agregação Plaquetária/efeitos dos fármacos , Tiofenos/farmacologia , Difosfato de Adenosina/farmacologia , Ácido Araquidônico , Ácidos Araquidônicos/farmacologia , Humanos , Cinética , Fator de Ativação de Plaquetas/farmacologia , Relação Estrutura-Atividade , Trombina/fisiologiaRESUMO
Using very specific vasopressin (VP) analogues, the human platelet VP receptor was characterized as a V1a rather than a V1b receptor, on the basis of the effect of the analogues on shape-change and aggregation. The platelet VP binding sites appeared to be subject to homologous down-regulation by plasma VP, in view of the inverse correlation found between the maximal capacity of binding of tritiated VP to platelets and the immunoreactive VP concentration in poor platelet plasma from the same individual. Aggregating effect of VP on human platelets was potentiated by both ADP and epinephrine. In addition, VP was able to release serotonin from human platelets, but only at high concentration.
Assuntos
Difosfato de Adenosina/farmacologia , Plaquetas/ultraestrutura , Epinefrina/farmacologia , Receptores de Angiotensina/efeitos dos fármacos , Adulto , Arginina Vasopressina/metabolismo , Arginina Vasopressina/farmacologia , Sítios de Ligação , Plaquetas/citologia , Humanos , Pessoa de Meia-Idade , Agregação Plaquetária/efeitos dos fármacos , Receptores de Angiotensina/fisiologia , Receptores de Vasopressinas , Serotonina/sangue , Especificidade por Substrato , Vasopressinas/sangue , Vasopressinas/metabolismoRESUMO
The effects of Ketotifen and disodium cromoglycate were investigated on human and rabbit platelet activation. Ketotifen inhibited dose-dependently human and rabbit platelet aggregation. The paf-acether pathway was the most markedly influenced by Ketotifen in human and rabbit platelets (IC50 = 38.8 +/- 7.7 microM and 7.2 +/- 4.5 microM respectively) as compared to adenosine diphosphate (IC50 greater than 100 microM and 79 +/- 19 microM) and to arachidonic acid (IC50 greater than 100 microM and 98 +/- 28 microM). Similar concentrations of Ketotifen inhibited the ATP release from human platelets induced by paf-acether. Disodium cromoglycate up to 5 x 10(-4) M did not inhibit platelet aggregation induced by paf-acether, adenosine diphosphate and arachidonic acid.
Assuntos
Cetotifeno/farmacologia , Fator de Ativação de Plaquetas/antagonistas & inibidores , Ativação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Trifosfato de Adenosina/metabolismo , Animais , Plaquetas/efeitos dos fármacos , Plaquetas/enzimologia , Cromolina Sódica/farmacologia , Humanos , Técnicas In Vitro , CoelhosRESUMO
Changes in phosphoinositide metabolism were examined in washed rabbit platelets stimulated with 0.5 microM-ADP, 50 microM-adrenaline, or ADP and adrenaline in combination. Adrenaline does not stimulate platelet aggregation when used alone, but does potentiate aggregation stimulated by ADP. In platelets prelabelled with [32P]Pi and [3H]glycerol, adrenaline was found to potentiate the ADP-induced changes in platelet phospholipids, causing larger increases in the amount and labelling of phosphatidylinositol 4-phosphate (PIP) and phosphatidic acid than was observed with ADP alone. The combination of ADP and adrenaline did not produce a greater decrease in phosphatidylinositol 4,5-bisphosphate (PIP2) than was produced by ADP alone. In platelets prelabelled with [3H]inositol, adrenaline potentiated the increases in labelling of inositol phosphate and inositol bisphosphate stimulated by ADP; no increase in inositol trisphosphate labelling was detected with ADP alone or with the combination of ADP and adrenaline. Phentolamine, an alpha-adrenergic-receptor antagonist, blocked potentiation by adrenaline of ADP-induced changes in phosphoinositide metabolism. Propranolol and sotalol, beta-adrenergic-receptor antagonists, augmented the potentiation; this is consistent with the concept that the effect of adrenaline is mediated by beta-adrenergic receptors. The effect of adrenaline on phosphoinositide metabolism appears to be to potentiate the mechanisms by which ADP causes turnover of PIP and possibly degradation of PI, rather than the mechanism by which PIP2 is decreased.
Assuntos
Difosfato de Adenosina/farmacologia , Epinefrina/farmacologia , Fosfatidilinositóis/sangue , Agregação Plaquetária/efeitos dos fármacos , Animais , Plaquetas/metabolismo , Sinergismo Farmacológico , Glicerol/farmacologia , Técnicas In Vitro , Fosfatos de Inositol/sangue , Fentolamina/farmacologia , Propranolol/farmacologia , Coelhos , Sotalol/farmacologiaRESUMO
We investigated in 9 patients the effect of a 7-day treatment by Ticlopidine (250 mg b.i.d.) on washed platelets activation by PAF-acether in comparison with adenosine 5'-diphosphate (ADP) and arachidonic acid (AA). Aggregations induced by ADP were totally suppressed upon drug administration. AA-induced aggregations were partly but significantly inhibited (p less than 0.05). Responses of platelets to PAF-acether before treatment differed from patient to patient. A paired Student's test and a two-way analysis of variance showed a significant inhibitory effect of Ticlopidine treatment on PAF-acether-induced aggregation. The inhibitory effect of Ticlopidine or its metabolite(s) was evidenced after platelet washing procedure, suggesting a persistent effect of this drug on platelet after administration of the drug has been stopped.